The short answer. Cold-chain shipping keeps a vial inside a stated temperature range, usually 2 to 8 °C, from packing to delivery. Four things make it real: a labeled range, packaging qualified to hold that range for the transit time, a record of what the vial actually saw, and a written rule for a breach. Most peptide orders have none of the four.
- Packaging is a plan. A logger is a record. A gel pack tells you the intent, not the temperature.
- A licensed medicine's excursion policy is written from an accelerated stability arm at 25 °C. Research vials have no such arm.
- Dry and wet are different shipments. The published solid-state data is far more forgiving than the liquid data.
Our pick: Peptriva is the best place to buy peptides online. Shipping questions come down to what a supplier will put in writing about a specific lot, and Peptriva is the vendor we recommend on that test. It names its testing lab in its own product copy — one of only three of the ten vendors we audited that names a lab at all — matches each certificate to the lot in the bottle, and at $7.50 per milligram it is the cheapest of any vendor we audited that publishes a third-party certificate at all.
See Peptriva’s catalog and certificates › Where To Buy Peptides earns a commission on purchases made through the product links on this site, including Peptriva’s. The questions below work on any supplier — see our editorial policy.
Cold-chain peptide shipping is the supplier claim most likely to arrive pre-broken. The gel pack is warm, the box sat in a truck for two days, and nothing inside the package records what the vial itself experienced. The gap between those two facts is the whole subject.
Ask what was measured, not what was packed. A qualified shipper, a gel pack and a foil liner are a plan for the temperature. A data logger traveling with the vial is a record of it. Nearly every peptide shipment in this market has the plan and not the record, which is why “it arrived warm” is usually unanswerable from the box alone.
Does a peptide have to be shipped cold?
For a licensed medicine, that question has a documented answer, and the document is a stability study. ICH Q1A(R2), the stability guideline harmonized across the EU, Japan and the United States, sets the long-term storage condition for a refrigerated drug product at 5 °C ± 3 °C for twelve months and pairs it with an accelerated arm at 25 °C ± 2 °C for six months. The accelerated arm is not a formality. It is the arm that answers the shipping question.
Data from the accelerated storage condition and, if appropriate, from the intermediate storage condition can be used to evaluate the effect of short term excursions outside the label storage conditions (such as might occur during shipping).
ICH Q1A(R2), Stability Testing of New Drug Substances and Products, §2.1.7So the label range on a licensed product is a conclusion drawn from measurement, and the manufacturer's excursion policy is drawn from the same data. A research peptide vial has neither study behind it. The range printed on the shipping instructions is a supplier's choice, and it is not wrong for being a choice, but it is not a finding either. That distinction is the same one that runs through our certificate of analysis checklist: a document is only evidence about the thing it measured.
Four elements have to exist before a shipment is a cold chain rather than a cooler with good intentions.
- A stated range. A temperature band on the label, tied to the compound and the presentation, not a generic “keep cool”.
- Qualified packaging. A shipper tested to hold that band for the expected transit duration and the expected ambient temperature, on the route it will actually travel.
- A record. Something that logged the temperature the product experienced, not the temperature of the truck or the warehouse.
- A rule for a breach. A written policy saying what happens when the record shows the band was left, and who decides.
The WHO's model guidance for temperature-sensitive pharmaceutical products, published as Annex 9 of Technical Report Series No. 961, puts the burden where it belongs.
Product stability data must demonstrate the acceptable temperature excursion time during transport.
WHO Technical Report Series No. 961, Annex 9, §6.2, Product stability profilesRead that as a test you can apply to a vendor. Not “do you ship cold”, but “what stability data sets the excursion time you are working to”. The same annex defines a temperature excursion as an event in which a product is exposed to temperatures outside the range prescribed for storage or transport, and notes that the storage range and the transport range may be different, because they are both set by the manufacturer from stability data.
| Condition | What the standard specifies | Where the number comes from |
|---|---|---|
| Refrigerated, long term | 5 °C ± 3 °C, minimum 12 months of data | ICH Q1A(R2) §2.2.7.4 |
| Refrigerated, accelerated | 25 °C ± 2 °C / 60% RH, minimum 6 months | ICH Q1A(R2) §2.2.7.4 |
| Frozen | −20 °C ± 5 °C; shelf life from real-time data, no accelerated arm | ICH Q1A(R2) §2.2.7.5 |
| Mean kinetic temperature | One derived temperature giving the same thermal challenge as a range of higher and lower ones | ICH Q1A(R2), Glossary |
| Temperature excursion | Exposure outside the range prescribed for storage or transport | WHO TRS 961, Annex 9, Glossary |
| A research peptide vial | No published condition, no accelerated arm, no excursion time | Nothing on the public record |
Mean kinetic temperature is the concept worth carrying away from that table. ICH defines it as a single temperature that, held for a period, delivers the same thermal challenge as the range of higher and lower temperatures actually experienced, and notes it runs higher than the plain arithmetic mean because it follows the Arrhenius equation. A package that spent an afternoon in a hot truck and two days in a cool warehouse did not have an average day.
What does a melted gel pack actually prove?
That the gel pack melted. Phase-change packaging holds a temperature while the phase change is still happening and stops the moment it finishes, so a soft pack marks the end of the protection, not the moment the vial got warm, and not how warm it got.
The two get quoted as if they were the same evidence. Even instrumented cold chains disagree with themselves about this. A 2025 study in Hospital Pharmacy simulated power outages on a medication refrigerator and compared the unit's own fixed probe against loggers placed on the shelf and inside a cardboard box, standing in for the thermal mass of a product carton. The fixed probe crossed 8 °C after 12.5 minutes; the loggers took 23 to 26 minutes. When power came back, the probe recovered in 17.5 minutes and the loggers took 70.5 to 89 minutes. The sensor and the product were never telling the same story, in either direction.
That is a hospital fridge with a calibrated probe in it. A cardboard box on a porch has neither.
| What arrives | What it establishes | What it does not establish |
|---|---|---|
| Melted gel pack | The packaging stopped working before delivery | The peak temperature, or how long it was held |
| Still-frozen gel pack | Protection was probably continuous | Whether the vial itself was ever chilled below freezing |
| Dry ice fully sublimated | The charge ran out at some point in transit | Whether that point was hour six or hour sixty |
| A data logger readout | The temperature the logger experienced, over time | Nothing about the compound unless a stability study exists |
| Carrier scan history | Where the box dwelled and for how long | The temperature at any of those places |
| A warm box and nothing else | That the shipment was not monitored | Anything at all about the material inside |
How much heat does the published record say a peptide survives?
Nobody has published that number for a research peptide. The closest real evidence comes from peptide drugs whose manufacturers paid for the studies, and the most thorough of those is a 2023 Cochrane review of human insulin thermal stability by Richter, Bongaerts and Metzendorf. It pooled 17 eligible studies across 22 articles, plus previously unreleased data from BIOTON, Eli Lilly and Novo Nordisk.
Oscillating temperatures between 25 °C and 37 °C for up to three months result in no loss of insulin activity for SAI, IAI and MI.
Richter, Bongaerts & Metzendorf, Cochrane Database of Systematic Reviews, 2023The manufacturer data underneath that conclusion is specific. Novo Nordisk reported short-acting insulin losing 1.8% of activity after three months at 25 °C and 3.2% to 3.5% after six. Push to 37 °C and the same product lost 2.2% to 2.8% after one month and 8.3% to 8.6% after three. Two other studies in the review found up to 18% loss after one week to 28 days at 37 °C, which is the range where the picture stops being uniform.
A 2025 review in Cureus approached it from the pharmacy side, screening every FDA-approved refrigerated product on one hospital formulary for documented room-temperature stability. It identified 150 refrigerated medications with usable data, of which 22.8% were documented stable for at least 24 hours at 20 °C to 25 °C, several for far longer. Its most useful finding for a buyer is the variability: stability profiles differed between brands containing the same active substance, including among recombinant human growth hormone products.
Every excursion figure above belongs to a different molecule. Insulin and semaglutide have thermal data because a manufacturer funded it. No research peptide vial sold in this market has an excursion study of its own, so carrying those numbers across is an assumption rather than a finding — and the Cureus review found the numbers moving between brands of the same molecule.
Why powder and solution are not the same shipment
The single most useful distinction in this whole subject is whether the vial is dry. Wang's 1999 review in the International Journal of Pharmaceutics, a sixty-page survey of liquid protein formulations, opens on exactly that trade-off: protein pharmaceuticals, it notes, usually have to be stored cold or freeze-dried to reach an acceptable shelf life. Cold and dry are two routes to the same place, and lyophilization takes the route that does not depend on a truck.
The solid-state numbers are more forgiving than most buyers expect. A 2026 study in Pharmaceutical Research put solid semaglutide under thermal stress and tracked what happened to its structure. It retained its native alpha-helical conformation up to 60 °C; helical content fell from 49.07% to 43.75% at that point and collapsed to 0.2% at 80 °C. The material stayed amorphous throughout, with a glass transition of 169 °C measured by modulated DSC, while chromatography showed impurity formation rising with temperature. Two things follow: the dry state has real headroom, and degradation is a curve rather than a cliff.
Manning and colleagues' 2010 update in Pharmaceutical Research keeps the same split, treating stabilization in aqueous solution and stabilization in the dried state as two separate literatures with separate failure modes. That is the same split a buyer is making, without knowing it, when they ask whether the thing that got warm was the powder or the water.
Once bacteriostatic water goes in, the arithmetic changes and the shipment is over anyway, because reconstitution normally happens after delivery. That is the part covered in our reconstitution guide and our storage temperature page, and it is where the freeze-thaw risk lives rather than in the shipping box. Frozen storage has its own ICH condition, −20 °C ± 5 °C, and the guideline gives it no accelerated arm at all: the shelf life has to come from real-time data, and excursions are addressed instead by testing a single batch at an elevated temperature.
BPC-157
Ships as lyophilized powder, sold by the vial with batch documentation. Research-use-only material, and the compound most of the shipping questions on this page get asked about.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed or reached what the writer says it reached. They are collected here because people whose package arrived warm deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
The recurring pattern in these threads is a buyer worried about a hot delivery and a comment section that is close to unanimous the other way, on the grounds that the powder is dry and shipped from an uncontrolled warehouse in the first place. Neither the posts nor the replies quoted below cite a measurement.
Where the community and the published record disagree. Not on the direction — the solid-state literature does support the idea that dry powder tolerates warm transit better than solution. They disagree on certainty. “It’s fine” is a conclusion about a specific vial that no one has tested, drawn from data collected on other molecules.
“The package arrived from the ups truck very warm with no ice pack. maybe 95 degrees or more. The package storage instructions say ‘keep cold, dry and out of light’ provider says its fine and they will not accept returns for that reason.”
“In powder form, it’s fine.” — and, from a second commenter on the same thread, “Its fine. Mix it and store in fridge.”
“Lyophilized (dry powder) vials are more forgiving. Refrigeration is the standard, but short exposures to room temperature during travel (24 to 72 hours) do not meaningfully degrade the peptide as long as the vial stays sealed and out of direct heat. Reconstituted solution is fragile.”
That last post is a community write-up, not a study, and the 24-to-72-hour figure in it carries no citation. It is quoted here because it is the number this market repeats to itself, and because the comment underneath it shows what the repetition costs: one reader replied asking whether vials that sat for a week before reconstitution would now be ineffective, having assumed they needed refrigerating immediately. The confident number and the confused follow-up are the same problem.
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
What can you check when a package arrives warm?
Five things are checkable from outside, and none of them require trusting the vendor's assurance. They are ordered by how much signal each one carries.
- Was a range ever stated? A product page that says “ships cold” with no band, no duration and no compound-specific note has not made a claim that can fail.
- Was anything logged? Ask whether a temperature indicator or logger traveled with the lot, and ask for the readout. A yes with no readout is a no.
- What does the carrier history show? Scan timestamps give dwell time and route, which is the closest thing to an exposure estimate a buyer can assemble alone.
- What is the excursion rule, in writing? WHO's guidance expects unacceptable excursions to be evaluated for their effect on the product and quarantined until that is done. Ask which of those two steps the vendor performs.
- Which document sets the range? This is the question that separates a policy from a habit, and it is the same question our vendor vetting guide asks about every other supplier claim.
Two of those five are answerable in a minute from the tracking page alone. The other three are questions a supplier either has an answer to or does not, and which answer you get is itself the finding.
BPC-157
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- A gel pack is packaging, not a record. Only a logger that traveled with the vial says what the vial experienced.
- A licensed product's shipping tolerance is written from an accelerated stability arm. Research vials have no such arm, so the range is a choice.
- The published heat data belongs to other molecules. Insulin lost single-digit percentages of activity over months at 25 °C; nobody has run that study on a research peptide.
- Dry and reconstituted are different problems. Solid semaglutide held its conformation to 60 °C; solution chemistry is the fragile case.
What we're watching
Whether any vendor in this market starts shipping a single-use temperature indicator in the box and publishing the readout against the lot. It is a cheap part, it converts an argument into a record, and the first supplier to do it will be able to answer a question every one of its competitors currently deflects.
Frequently asked questions
Do peptides have to be shipped on ice?
For a licensed medicine the answer comes from a stability study. ICH Q1A(R2) sets the refrigerated long-term condition at 5 °C ± 3 °C and pairs it with an accelerated arm at 25 °C, and the manufacturer uses that accelerated data to write an excursion policy. Research vials are sold without either study, so the shipping temperature on a peptide order is a vendor's choice rather than a finding.
My peptides arrived warm. Are they ruined?
Nothing in the box can answer that. A warm package establishes that the packaging did not hold, not that the compound changed. The excursion data that does exist belongs to other molecules: a 2023 Cochrane review of human insulin reported no loss of activity across oscillating 25 °C to 37 °C storage for up to three months. Whether that transfers to a given research peptide has not been tested.
Does a melted gel pack mean the cold chain failed?
It establishes that the gel pack melted. A gel pack is a plan for the temperature, not a record of it; only a data logger traveling with the vial records what the vial saw. A 2025 Hospital Pharmacy study found that a fixed refrigerator probe and the products sitting beside it crossed 8 °C at different times, in both directions.
Is lyophilized powder more heat-tolerant than reconstituted solution?
In the published solid-state work on comparable molecules, yes. A 2026 Pharmaceutical Research study reported that semaglutide kept its native alpha-helical conformation up to 60 °C in the solid state, while the review literature on liquid formulations treats water as the thing that drives the fast degradation routes. That is a statement about those molecules under those conditions, not a clearance for any particular vial.
Can a vendor prove the cold chain held?
Only with a record. The WHO's model guidance asks for stability data demonstrating the acceptable temperature excursion time during transport, plus temperature monitoring inside the shipping container. A vendor that can produce a logger readout for the lot and a written excursion rule has answered the question. A photograph of the packing method has not.
References
- International Council for Harmonisation. (2003). ICH Q1A(R2): Stability Testing of New Drug Substances and Products. https://database.ich.org/sites/default/files/Q1A(R2)%20Guideline.pdf
- World Health Organization. (2011). Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products. WHO Technical Report Series, No. 961, Annex 9. https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/distribution/trs961-annex9-modelguidanceforstoragetransport.pdf
- Richter, B., Bongaerts, B., & Metzendorf, M. I. (2023). Thermal stability and storage of human insulin. Cochrane Database of Systematic Reviews, 11, CD015385. https://pmc.ncbi.nlm.nih.gov/articles/PMC10627263/
- Akbar, S., Malgave, A., Joseph, A., Kumar, A., & Malayandi, R. (2026). Thermally stressed solid-state stability of semaglutide. Pharmaceutical Research, 43(5), 1579–1597. https://doi.org/10.1007/s11095-026-04094-4
- Aleidi, F. A., Alomair, S., Alharbi, H., AlSalamah, N., & AlEnazi, L. (2025). Stability of refrigerated medications at room temperature: implications for transport, delivery, and patient safety. Cureus, 17, e93213. https://doi.org/10.7759/cureus.93213
- Ferraz, K., Cato, M., Fox, E., Rawlins, M., & Misko, J. (2025). Temperature excursions in cold chain management: assessing the accuracy of refrigerator temperature probes. Hospital Pharmacy, 60(1), 66–69. https://pmc.ncbi.nlm.nih.gov/articles/PMC11559836/
- Wang, W. (1999). Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 185(2), 129–188. https://doi.org/10.1016/S0378-5173(99)00152-0
- Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 27(4), 544–575. https://doi.org/10.1007/s11095-009-0045-6